Treatment with Trikafta improves lung function in people with cystic fibrosis (CF) who are not eligible for treatment…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Clinicians who are caring for people with cystic fibrosis (CF) should talk to their patients about pregnancy and family…
Six months of treatment with Trikafta does not substantially alter digestive symptoms in people with cystic fibrosis (CF), new…
For children with cystic fibrosis (CF), newborn screening is associated with markedly improved real-world outcomes, including earlier…
People with cystic fibrosis (CF) who start on the triple therapy Trikafta may be at greater risk of…
Treatment with Orkambi (lumacaftor/ivacaftor) and/or Symdeko (tezacaftor/ivacaftor) may lessen liver damage in children and adolescents with cystic fibrosis…
Treatment with Trikafta can help people with cystic fibrosis…
Treatment with SP-101, an investigational gene therapy that Spirovant Sciences is developing for people with cystic…
Since the approval of Trikafta in the U.S., Nationwide Children’s Hospital in Ohio…
A platform to help people with cystic fibrosis (CF) better adhere to inhalation treatment, called the CFHealthHub, led to…